Business News • PR NewsWire • Three-Year Follow-Up Data Confirm Safety and Survival Benefit in Chinese Liver Failure Patients Treated With ELAD® Bioartificial Liver

Three-Year Follow-Up Data Confirm Safety and Survival Benefit in Chinese Liver Failure Patients Treated With ELAD® Bioartificial Liver

Three-Year Follow-Up Data Confirm Safety and Survival Benefit in Chinese Liver Failure Patients Treated With ELAD® Bioartificial Liver

SAN DIEGO, Oct. 13 /PRNewswire/ -- Vital Therapies, Inc., (VTI) today announced that a poster is being presented at the American Association for the Study of Liver Diseases (AASLD) meeting in Boston on Tuesday, November 2nd. It confirms that previously reported findings of improved transplant free s

View More : http://www.prnewswire.com/news-releases/three-year-follow-up-data-confirm-safety-and-survival-benefit-in-chinese-liver-f...

Releted News by prnewswire

IBM to Build Global R&D Lab at University of Melbourne

El premio Curry Stone Design Prize 2010 fue otorgado a la empresaria que está detrás de una innovadora línea de productos para la higiene femenina, basados en hojas de banano